18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Nuclear Medicine

• Publication date

  2007-12-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.2967/jnumed.107.046292PMID 18077522
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review

  2007influential reference
• Revised response criteria for malignant lymphoma.

  2007influential reference
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007influential reference
• The role of FDG-PET scans in patients with lymphoma.

  2007cited by this paper
• Positron-emission tomography and assessment of cancer therapy.

  2006cited by this paper
• Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma.

  2006cited by this paper
• 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

  2006influential reference
• Role of positron emission tomography in lymphoma.

  2005cited by this paper
• Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

  2005influential reference
• Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

  2001cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

  1999cited by this paper

• The effect of changes in tumor volume and the level of FDG absorption on the duration of progression-free survival in patients with lymphomas

  2025cites this paper
• PET/CT in Hodgkin Lymphoma: An Update.

  2022cites this paper
• Positron emission tomography/computed tomography in the management of Hodgkin and B‐cell non‐Hodgkin lymphoma: An update

  2021cites this paper
• Clinical Imaging Technology and the Diagnosis in Patient-centered Interdisciplinary Care.

  2019cites this paper
• The role of PET/CT in the modern treatment of Hodgkin lymphoma.

  2019cites this paper
• Continuing education 18 F-FDG-PET / CT in lymphoma : Two decades of experience

  2017cites this paper
• CT perfusion in evaluation of post therapy cervical lymphoma

  2016cites this paper
• Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.

  2016cites this paper
• PET Scan for HL Restaging

  2016cites this paper
• Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.

  2016cites this paper
• Development of a single vial kit formulation of [99mTc]-labeled doxorubicin for tumor imaging and treatment response assessment-preclinical evaluation and preliminary human results.

  2015cites this paper
• PET in lymphoma: who, when, how often, pitfalls?

  2015cites this paper
• Assessment of the nature of residual masses at end of treatment in lymphoma patients using volume perfusion computed tomography

  2014cites this paper
• 18F-FDG-PET/CT in lymphoma: two decades of experience.

  2012cites this paper
• Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.

  2012cites this paper
• 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma

  2012cites this paper
• High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database

  2012cites this paper
• 18F-FDG-PET/CT in lymphoma: two decades of experience.

  2012cites this paper
• FDG-PET/CT in lymphoma.

  2011cites this paper
• Impact of FDG-PET/CT in the management of lymphoma

  2011cites this paper
• Der Stellenwert der Positronen-Emissions-Tomographie (18 F- FDG-PET) in Diagnostik und Therapiekontrolle bei Hodgkin- Lymphomen

  2011cites this paper
• Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma

  2011cites this paper
• Decreased brain FDG uptake in patients with extensive non-Hodgkin’s lymphoma lesions

  2010cites this paper
• Pediatric Applications for PET/CT and SPECT/CT

  2010cites this paper
• PET imaging for pediatric oncology: An assessment of the evidence

  2010cites this paper
• [Imaging in oncology and international rules for evaluation: the nuclear medicine].

  2009cites this paper
• The utility of PET/CT with 18F-FDG in the study of Hodgkin's lymphoma and non-Hodgkin's lymphoma Utilidade da PET/CT, (18F-FDG), no estudo do linfoma Hodgkin e linfoma não Hodgkin

  2009cites this paper
• Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

  2009cites this paper
• Evidencias en Medicina Nuclear. Seleccin de publicaciones, enero-junio 2008

  2008cites this paper
• Tomographie à émission de positons et lymphomes

  2008cites this paper
• 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response*

  2008cites this paper